NCT00733174Unknown4 期
Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Effect of rosiglitazone vs. placebo on exercise tolerance
研究概览
简要总结
Subjects with impaired glucose tolerance will be randomized to either rosiglitazone or placebo for a 18 month period. The study will look at baseline, 12 month and 18 month data for exercise tolerance, coronary artery calcification and diabetes indicators.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 25 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must sign the informed consent to participate in the study.
- •Male or female adults ages 25-75 years.
- •Female subjects must be postmenopausal (i.e., > 6 months without menstrual period), surgically sterile, or using effective barrier contraceptive measures (Intra-Uterine Device (IUD), diaphragm with spermicide or condom with spermicide).
- •Women of childbearing potential must use effective barrier contraceptive measures for at least 1 month prior to visit 1, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study medication.
- •Female subjects of childbearing potential must have a negative urine pregnancy test.
- •Subjects must have an FPG < 126 mg/dL at Screening 1 AND Screening 2, a C-peptide > 2.0 ng/mL and a HbA1c <6.5%.
- •Subjects must have a Body Mass Index 25-40 (must be < 300 lbs).
- •Subjects must have a 2 hour post-prandial glucose 140-199 mg/dL at Screening 1 AND Screening
- •If the 2 hour post-prandial glucose result is 130-139 mg/dL at Screening 2, subjects will be allowed to repeat the OGTT.
排除标准
- •Women who are lactating, pregnant, or planning to become pregnant during the study will be excluded.
- •Women using hormone contraception or on hormone replacement therapy will be excluded.
- •Subjects with any clinically significant abnormality identified on the Screening physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study will also be excluded.
- •Use of any other investigational agents or participation in any other investigational studies during the study period will not be allowed.
- •Patients will also be excluded if there is a presence of clinically significant hepatic disease or patient with LFT levels > 2 times the upper limit of normal laboratory range
- •Subjects with a documented history of significant hypersensitivity (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to thiazolidinediones
- •Subjects with any contraindications to rosiglitazone
- •Presence of unstable or severe (New York Heart Association-NYHA class 3 or 4) angina, including angina requiring continual nitrate treatment for symptomatic relief, or coronary insufficiency
- •Subjects with HYHA class 3 or 4 of congestive heart failure requiring drug therapy; systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg
- •History of cancer (except non-melanomatous skin carcinoma)
- •Active alcohol or drug abuse within the last 6 months
- •Subjects with chronic diseases requiring periodic or intermittent treatment with oral or intravenous corticosteroids
- •Subjects who are unable to understand dosing directions or swallow study medications
- •Subjects who are currently smoking
- •Subjects unable to adhere to protocol requirements.
- •Persons with angina or any other cardiac or pulmonary symptoms that would potentially limit exercise performance will be excluded.
- •Persons taking prescription or over-the-counter weight loss medications or persons on a weight loss program with ongoing weight loss, or starting an intensive exercise program within 30 days of screening will also be excluded.
研究组 & 干预措施
2
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
1
Experimental
Rosiglitazone
干预措施: Rosiglitazone (Drug)
结局指标
主要结局
Effect of rosiglitazone vs. placebo on exercise tolerance
时间窗: 18 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
4 期
Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty LiverChronic Hepatitis C InfectionFatty LiverNCT00274495Beth Israel Medical Center30
已完成
3 期
Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY TrialCoronary Artery Bypass GraftingDiabetesNCT00169832Laval University193
Unknown
3 期
Prevention of Corticosteroid-induced Glucose IntoleranceGlucose IntoleranceNCT00240604Hadassah Medical Organization100
终止
3 期
Glitazones and Endothelial Function (GATE)Diabetes MellitusNCT00203632University of Calgary40
已完成
3 期
A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus PatientsDiabetes Mellitus, Type 2Type 2 Diabetes MellitusNCT00349427GlaxoSmithKline256